Recently, Hefei Leecan Pharmaceutical Co., Ltd. applied for two phase III clinical trials of inhaled aerosols, which achieved efficient breakthroughs in the relevant processes of the Provincial Hospital Affiliated to Fuzhou University, the clinical research center. The whole process from central research to ethical approval took only five working days, breaking the hospital's record of clinical trial approval efficiency and injecting "acceleration" into the clinical transformation of Leecan products.

As the sponsor of the project, Leecan pharmaceutical works closely with Nanjing Yinguang Pharmaceutical Technology Co., Ltd., a clinical research organization. Relying on the professional undertaking of the team of director Xu nengluan from the infectious diseases department of the provincial hospital, as well as the collaboration of the clinical trial research center, institutional office, ethics committee and other departments of the hospital, Leecan pharmaceutical realizes the parallel promotion of the whole process through the "green channel". The center arranged special docking of specialists to optimize the linear series connection in the traditional approval process into efficient parallel connection, minimizing the non-technical waiting time.

 This efficient implementation is not only the result of the hospital's mechanism innovation driving efficiency improvement, but also reflects Leecan Pharmaceutical's continuous pursuit of clinical research quality and efficiency. In 2026, Leecan Pharmaceutical officially established the Clinical Management Department to strengthen collaborative linkage with CROs and various clinical research centers, establish an efficient project management mechanism and full-process quality control system, improve clinical operation efficiency, focus on overcoming the clinical research pain points of high-end inhalation preparations such as inhalation aerosols, and make cutting-edge achievements benefit patients earlier.

The efficient advancement of these two Phase III clinical trials for inhalation aerosols demonstrates Leecan Pharmaceutical's comprehensive collaborative capabilities in the high-end inhalation formulation field, from technological breakthroughs to clinical translation. Leecan Pharmaceutical will continue to focus on unmet clinical needs, deepen its integrated inhalation delivery technology platform, and build a full product pipeline covering mainstream inhalation dosage forms. With China manufacturing and China innovation, we will safeguard China's respiratory health and enable Chinese patients to access high-quality inhalation formulations on par with global standards!